CLDI Calidi Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1855485 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY19.9%
TTM EPS YoY192.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-373.6%
ROA-163.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets70.5%
Debt / equity0.41x
Current ratio1.27x
Interest coverage-252.18x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.70M | $2.56M | $2.59M | $2.36M | $2.36M | $2.59M | $2.42M | $1.81M |
| SG&A expense | $1.64M | $1.59M | $1.60M | $2.11M | $2.69M | $3.07M | $2.64M | $2.21M |
| Operating income | -$4.34M | -$4.15M | -$4.19M | -$4.47M | -$5.05M | -$5.66M | -$5.06M | -$4.03M |
| Interest expense | $23,000 | $22,500 | $22,500 | $0 | $27,000 | $40,000 | $100,000 | $100,000 |
| Pretax income | -$3.64M | -$4.16M | -$4.10M | -$4.06M | -$5.17M | -$5.76M | -$5.06M | -$4.14M |
| Income tax | $9,000 | $5,000 | $4,000 | -$2,000 | $10,000 | $4,000 | $3,000 | $3,000 |
| Net income | -$3.65M | -$4.16M | -$4.11M | -$4.06M | -$5.15M | -$5.71M | -$4.99M | -$4.10M |
| EBITDA | -$3.93M | -$3.71M | -$3.76M | -$4.04M | -$4.62M | -$4.95M | -$4.67M | -$3.63M |
| EPS (basic) | -1.47 | -2.94 | -0.43 | — | -35.25 | -31.75 | -2.21 | — |
| EPS (diluted) | -1.47 | -2.94 | -0.43 | — | -35.25 | -31.75 | -2.21 | — |
| Weighted avg. shares (diluted) | 2.48M | 1.42M | 10.31M | — | 307,000 | 180,000 | 2.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.17M | $4.29M | $6.85M | $5.82M | $10.59M | $5.38M | $10.78M | $9.81M |
| Current assets | $4.74M | $5.43M | $7.35M | $6.26M | $11.03M | $6.05M | $11.49M | $10.23M |
| PP&E, net | $704,000 | $775,000 | $758,000 | $781,000 | $849,000 | $929,000 | $795,000 | $869,000 |
| Total assets | $5.52M | $7.20M | $9.59M | $8.86M | $14.03M | $9.35M | $15.06M | $14.18M |
| Current liabilities | $3.73M | $3.24M | $3.84M | $3.94M | $5.19M | $5.35M | $5.43M | $9.50M |
| Short-term debt | $668,000 | $45,000 | $23,000 | $90,000 | $472,000 | $820,000 | $1.16M | $3.22M |
| Long-term debt | $0 | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 | $600,000 |
| Total debt | $668,000 | $645,000 | $623,000 | $690,000 | $1.07M | $1.42M | $1.75M | $3.82M |
| Total liabilities | $3.89M | $4.07M | $4.66M | $5.10M | $6.83M | $7.28M | $7.76M | $12.21M |
| Shareholders' equity | $1.63M | $3.13M | $4.93M | $3.76M | $6.92M | $1.76M | $6.94M | $1.53M |
| Net debt | -$3.50M | -$3.65M | -$6.23M | -$5.13M | -$9.52M | -$3.96M | -$9.02M | -$5.99M |
| Shares outstanding | 2.89M | 2.08M | 11.79M | 451,076 | 6.91M | 2.88M | 31.79M | 1.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.34M | -$4.35M | -$4.12M | -$5.04M | -$4.24M | -$4.88M | -$7.13M | -$5.42M |
| Investing cash flow | -$23,000 | -$33,000 | -$5,000 | -$79,000 | -$27,000 | -$57,000 | -$7,000 | -$5,000 |
| Financing cash flow | $2.25M | $1.83M | $5.16M | $340,000 | $9.48M | -$469,000 | $8.11M | $13.11M |
| Depreciation & amortization | $417,000 | $438,000 | $426,000 | $423,000 | $427,000 | $710,000 | $394,000 | $393,000 |
| Stock-based compensation | $62,000 | $157,000 | $231,000 | $450,000 | $529,000 | $522,000 | $607,000 | $626,000 |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.